NovoCure Stock Forecast, Price & News

NovoCure (NASDAQ:NVCR) Frequently Asked Questions

Is NovoCure a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovoCure in the last twelve months. There are currently 1 sell rating, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NovoCure stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVCR, but not buy additional shares or sell existing shares.
View analyst ratings for NovoCure or view top-rated stocks.

How has NovoCure's stock price been impacted by COVID-19?

NovoCure's stock was trading at $67.38 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, NVCR stock has decreased by 0.3% and is now trading at $67.18.
View which stocks have been most impacted by COVID-19.

When is NovoCure's next earnings date?

NovoCure is scheduled to release its next quarterly earnings announcement on Thursday, February 24th 2022.
View our earnings forecast for NovoCure.

How can I listen to NovoCure's earnings call?

NovoCure will be holding an earnings conference call on Thursday, February 24th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were NovoCure's earnings last quarter?

NovoCure Limited (NASDAQ:NVCR) issued its quarterly earnings results on Thursday, October, 28th. The medical equipment provider reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.06) by $0.07. The medical equipment provider had revenue of $133.61 million for the quarter, compared to the consensus estimate of $141.22 million. NovoCure had a negative net margin of 4.94% and a negative trailing twelve-month return on equity of 6.50%. NovoCure's revenue was up .7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.09 earnings per share.
View NovoCure's earnings history.

What price target have analysts set for NVCR?

6 brokers have issued 1 year price targets for NovoCure's shares. Their forecasts range from $70.00 to $250.00. On average, they anticipate NovoCure's share price to reach $154.83 in the next year. This suggests a possible upside of 130.5% from the stock's current price.
View analysts' price targets for NovoCure or view top-rated stocks among Wall Street analysts.

Who are NovoCure's key executives?

NovoCure's management team includes the following people:

• Asaf Danziger, Chief Executive Officer & Director
• Wilhelmus C. M. Groenhuysen, Chief Operating Officer
• Ashley Cordova, Chief Financial Officer (LinkedIn Profile)
• Uri Weinberg, Chief Science Officer
• Ely Benaim, Chief Medical Officer (LinkedIn Profile)

What is Asaf Danziger's approval rating as NovoCure's CEO?

17 employees have rated NovoCure CEO Asaf Danziger on Glassdoor.com. Asaf Danziger has an approval rating of 90% among NovoCure's employees.

Who are some of NovoCure's key competitors?

Some companies that are related to NovoCure include Fresenius SE & Co. KGaA (FSNUY), Insulet (PODD), Teleflex (TFX), Abiomed (ABMD), Penumbra (PEN), Tandem Diabetes Care (TNDM), Globus Medical (GMED), Inspire Medical Systems (INSP), Integra LifeSciences (IART), ShockWave Medical (SWAV), ICU Medical (ICUI), iRhythm Technologies (IRTC), Inari Medical (NARI), Merit Medical Systems (MMSI) and Nevro (NVRO).
View all of NVCR's competitors.

What other stocks do shareholders of NovoCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NovoCure investors own include Chembio Diagnostics (CEMI), Prospect Capital (PSEC), Calumet Specialty Products Partners (CLMT), NVIDIA (NVDA), Two Harbors Investment (TWO), BlackRock Capital Investment (BKCC), Viper Energy Partners (VNOM), Roku (ROKU), salesforce.com (CRM) and Square (SQ).

What is NovoCure's stock symbol?

NovoCure trades on the NASDAQ under the ticker symbol "NVCR."

Who are NovoCure's major shareholders?

NovoCure's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (9.26%), Frontier Capital Management Co. LLC (0.42%), Taylor Frigon Capital Management LLC (0.04%), Exchange Traded Concepts LLC (0.03%), Sciencast Management LP (0.01%) and Cutler Group LP (0.00%). Company insiders that own NovoCure stock include Asaf Danziger, Ashley Cordova, Ely Benaim, Frank X Leonard, Gabriel Leung, Jeryl L Hilleman, Martin J Madden, Michael J Ambrogi, Pritesh Shah, Todd Christopher Longsworth, Uri Weinberg, Wilhelmus Cm Groenhuysen and William F Doyle.
View institutional ownership trends for NovoCure.

Which institutional investors are buying NovoCure stock?

NVCR stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Frontier Capital Management Co. LLC, Exchange Traded Concepts LLC, Sciencast Management LP, Lattice Capital Management LLC, Taylor Frigon Capital Management LLC, AdvisorNet Financial Inc, and IFP Advisors Inc.
View insider buying and selling activity for NovoCure or or view top insider-buying stocks.

How do I buy shares of NovoCure?

Shares of NVCR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NovoCure's stock price today?

One share of NVCR stock can currently be purchased for approximately $67.18.

How much money does NovoCure make?

NovoCure has a market capitalization of $6.97 billion and generates $494.37 million in revenue each year. The medical equipment provider earns $19.81 million in net income (profit) each year or ($0.27) on an earnings per share basis.

How many employees does NovoCure have?

NovoCure employs 1,023 workers across the globe.

What is NovoCure's official website?

The official website for NovoCure is www.novocure.com.

Where are NovoCure's headquarters?

NovoCure is headquartered at NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF.

How can I contact NovoCure?

NovoCure's mailing address is NO. 4 THE FORUM GRENVILLE STREET, ST. HELIER Y9, JE2 4UF. The medical equipment provider can be reached via phone at 441534756700 or via email at [email protected].